Pfizer Gets Support For Arthritis Drug ApprovalVW Staff
Pfizer Inc. (NYSE:PFE) has moved one step closer to approval of a drug that will improve options in the treatment of Rheumatoid Arthritis. An advisory panel specializing in arthritis medication voted 8-2 in favor of the drug stating that it's benefits outweighed its potential risks. The support of the committee brings the company one step closer to approval of the drug, which could be a boon to the company's future sales . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.